Dover, Delaware – April 3, 2023 – Rexis Biotech Inc. (“REXIS”) is pleased to announce its continued growth and expansion into the legal cannabis markets through a strategic partnership with Redbud Roots, Inc. (“Redbud”).
Redbud is a full-service premium cannabis company serving legal age recreational customers and medical marijuana patients throughout Michigan. Redbud has built an award-winning product line and management team supporting industry growth through product and manufacturing innovations while being completely vertically integrated as a farm to table manufacturer and retailer. In 2021, Redbud was the first licensed cannabis manufacturer in the state of Michigan to bring an approved cannabis drink to market.
Alex Leonowicz, Redbud COO, stated, “We have been working with Ryan, Keith and the Rexis team since 2019. Their dedication and commitment significantly advanced the development of our edible and infused beverage line in the ever-competitive cannabis marketplace. Our products now stand apart from the competition. The Company is dynamic, offering a myriad of solutions for individuals currently working in or looking to enter the cannabis industry. We’re excited to watch this Company evolve and look forward to a long term partnership.”
Keith Bushfield, Rexis President & CEO, commented “Our partnership with Redbud has been nothing short of exceptional. The Redbud team utilizes true best production methods while always striving to build the next great product line. Redbud’s adoption of our technology to power their edible and drink products is a testament to the unique value proposition our delivery system provides. The results have already proven themselves with faster than anticipated product adoption and sell through with their Fruit Stand gummies. We look forward to working with Redbud and growing our long-term relationship as we work to further expand product offerings and drive revenue.”
About Rexis Biotech, Inc.
Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams.
Media Inquires
Ryan Erving
(415) 314 – 7133
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
